A Verification Study for Implementing the Revised CLSI Breakpoints. Summary. Glossary CDC 1
|
|
- Bernard Floyd
- 6 years ago
- Views:
Transcription
1 A Verification Study for Implementing the Revised CLSI Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance National Center for Emerging and Zoonotic Infectious Disease The findings and conclusions in this presentation have not been formally disseminated by the Centers for Disease Control and Prevention and should not be construed to represent any agency determination or policy Summary Why a study is needed Study design Data analysis 2 AST Device Glossary A commercial antimicrobial susceptibility testing method Examples: MicroScan, BD Phoenix, Vitek2, Etest Reference AST method A standardized, non proprietary antimicrobial susceptibility test method Examples: CLSI frozen broth microdilution, disk diffusion 3
2 Glossary Federal laboratory regulation The regulation: CLIA The enforcers: CAP and Joint Commission FDA The federal agency which regulates antimicrobials & the AST devices Information is in the product label or package insert 4 CLSI Glossary A not for profit laboratory standards organization Describes AST reference methods & AST interpretive criteria AST interpretive criteria Criteria for categorizing a bacterial isolate as susceptible, intermediate, or resistant to an antimicrobial Also known as breakpoints 5 Verification Glossary The documentation of either commercial or laboratory developed tests to determine or confirm test performance characteristics before the test system is used for patient testing Validation The documentation that a test which has already been verified is repeatedly giving the expected results as the test is performed over a period of time. 6
3 Why are there Different Breakpoints for the Same Drug? CLSI FDA Different types of organization Different processes for setting breakpoints 7 Breakpoint Differences Cephalosporin Breakpoints for Enterobacteriaceae CLSI & FDA ceftriaxone breakpoints revised in Breakpoint Differences Carbapenem Breakpoints for Enterobacteriaceae 9
4 Updating FDA Breakpoints Ceftriaxone breakpoints revised 10 Which Breakpoints Can My Lab Use? Lab regulatory agencies Joint Commission & CAP allow labs to use either CLSI or FDA breakpoints Lab regulatory agencies also require that commercial antimicrobial susceptibility testing (AST) devices Either meet FDA performance standards or Be verified for acceptable performance by the lab using the test 11 The Issue AST device manufacturers are required by law to use FDA breakpoints Panels can be updated with new drug dilutions for reporting lower MICs if the manufacturer has previous clearance for those drug dilutions Panels cannot be updated to provide new interpretations based upon non FDA breakpoints 12
5 Consult with stakeholders If using disk diffusion you can implement revised breakpoints without a validation study If using a device, a validation study is needed 13 IDSA notified members of revised CLSI breakpoints See Appendix A Validation Suggestion Why is a Study Needed? To meet CLIA Requirement (b)(2): Prior to reporting patient test results, the laboratory is responsible for establishing the performance specifications for each modified FDA-cleared or approved test system, each test system not subject to FDA clearance or approval, and each test system for which the manufacturer does not provide performance specifications. The establishment of method performance specifications should provide evidence that the accuracy, precision, analytical sensitivity, and analytical specificity of the procedure is adequate to meet the clients' needs as determined by the laboratory director and clinical consultant. 15
6 The Purpose of the Study To evaluate whether an AST device meets the FDA required category agreement FDA requirements for AST devices 90% essential agreement 90% category agreement This requirement has already been met for all dilutions reported by an AST device ndguidance/guidancedocuments/ucm htm 16 What is Essential Agreement? MIC results from a reference method and a device method are within a single doubling dilution Example: Klebsiella pneumoniae meropenem MIC (µg/ml) Reference broth microdilution 1 Device Device 2 4 Device 3 2 No essential agreement 17 What is Category Agreement? Category agreement for Susceptible, Intermediate, and Resistant Example: Zone diameter vs. MIC 18
7 Category Agreement Antimicrobial with S, I, R breakpoints of 1/2/4 Test Method MIC (µg/ml) Reference MIC (µg/ml) Example: MIC vs. MIC 19 If essential agreement has already been established, then why does category agreement need to be evaluated? Answer: It is possible to have essential agreement without category agreement Reference MICs Category Agreement Without Essential Agreement Hypothetical experiment: 30 isolates of Enterobacteriaceae were tested for meropenem susceptibility by reference MIC method and an AST device. New S/I/R breakpoints: 1/2/4 Test MICs Essential agreement = 66% Category agreement = 100% 21
8 Essential Agreement Without Category Agreement Hypothetical example: 30 isolates of Enterobacteriaceae were tested for meropenem susceptibility by reference MIC method and an AST device. Test MICs New breakpoints: 1/2/ Essential agreement = 100% Category agreement = 63% Reference MICs Interpretation for Reference Method Category Errors Interpretation for Test Method Type of Error Susceptible Intermediate Minor error Susceptible Resistant Major error Intermediate Susceptible Minor error Intermediate Resistant Minor error Resistant Intermediate Minor error Resistant Susceptible Very major error 23 Acceptable Results No standards for a study like this Must establish before starting the study Suggestion: Category agreement 90% No more than 1 major error No very major errors 24
9 Calculation Category agreement = # of isolates with the same interpretive result as the reference method # of isolates tested X A Study to Implement the Revised CLSI Cephalosporin and Carbapenem Breakpoints Availability of Concentrations of Antimicrobial Agents Needed to Implement Revised CLSI Breakpoints on Commercial AST Panels Antimicrobial Agent MicroScan Phoenix Sensititre Vitek2 Etest Aztreonam x 1 x x x x Cefazolin (2011 or later) 2 (2011 or later) x (Fall 2011) - (2011 Cefotaxime (2011 or later) or later) x x x (2011 or Ceftriaxone x later) x x x Ceftazidime x x x x x Doripenem x (2011 or later) x x x (2011 or (2012 or Ertapenem (2011 or later) later) x later) x Imipenem x x x x x Meropenem x x x x x 1 x = Available on one or more routine panels/cards as of 1/5/11 2 Projected availability
10 Possible Isolate Selection Revised Isolates Breakpoints to Test Carbapenems 5 carbapenemase (+) 5 Modified Hodge Test (-)( ) and elevated carbapenem MICs 20 other Enterobacteriaceae Cephalosporins 5 ESBL (+) and Aztreonam 5 ESBL (-)( ) and ESBL screen positive 20 other Enterobacteriaceae (preferably with MICs within S range using old BPs) Labs may consider testing more isolates Reference Method for the Validation Study CLSI reference broth microdilution frozen CLSI agar dilution CLSI disk diffusion The most accessible method 29 Procedures Test all isolate by the test AST method & the reference AST method Test isolates by both methods on the same day Prepare each inoculum from the same subculture plate If possible, use the same inoculum suspension (e.g. 0.5 McFarland equivalent) Use methods that you will use routinely Don t forget about quality control 30
11 Example: Data Collection Isolate ID Test AST Microscan Panel MIC (µg/ml) Reference AST Disk Diffusion Zone Diameter (mm) Isolate ID Test AST Microscan Panel MIC (µg/ml) Reference AST Disk Diffusion Zone Diameter (mm) BVS BVS BVS BVS BVS BVS BVS BVS BVS BVS BVS BVS BVS BVS BVS BVS BVS BVS BVS BVS BVS BVS BVS BVS BVS BVS BVS BVS BVS BVS Example: Scattergram MIC (ug/ml) Zone diameter (mm) 32 Example: Identify Errors Minor errors = 2, Major errors = 1, Very major errors = 0 Category agreement = = 0.90 or 90% 33
12 Documentation The study is needed to fulfill CLIA regulation If it is not documented, you didn t do it Documentation includes: Study procedure Results: data table and/or scattergram Calculations Conclusion statement Validation results must be approved by laboratory director 34 What if the results are unacceptable? 1-2 isolates with discrepant results could indicated random error >2 isolates with discrepant results may indicate systematic error caused by : Technical problems with the methods used in the study Discordance between test method and reference method 35 Unacceptable Results cont. Assessing error type Random errors unlikely to occur upon repeat testing Systemic technical errors will not repeat if the technical problem(s) is addressed Errors caused by a discordance between methods will repeat 36
13 Unacceptable Results cont. Review the procedures looking for technical errors Repeat testing can be done, but avoid repeating only isolates with discrepant results Decide on a systematic approach to repeat testing (e.g., repeat 1 to 2 isolates with nondiscrepant results for every one isolate with discrepant results) 37 Unacceptable Results cont. Calculate category agreement and error rates A) Using original data B) Using repeat data If the repeat study results meet the acceptability requirement, then Document the original results Document the repeat results Describe likely source of error 38 Unacceptable Results cont. Discordance between methods cannot be fixed by troubleshooting Consult manufacturer 39
14 The AST Manufacturer Cannot: Provide software or alter devices to provide non-fda breakpoints Can: Provide general instructions for how to customize the device expert system to apply the revised breakpoints Alternatively, labs can implement the revised breakpoint in their laboratory information 40 Applying New Breakpoints to Etest Applying revised breakpoints to Etest results is a modification of a FDA-cleared device A validation study is needed 41 Qs & As Q: What if some of the carbapenemaseproducing isolates test carbapenemsusceptible or the ESBL-producing isolates test cephalosporin-susceptible A: The purpose of this study is to determine if the category agreement between the test and reference AST methods are within acceptable limits regardless of underlying resistance mechanisms in the challenge isolates. 42
15 Qs & As Q: If we aren t scoring results by resistance mechanism, why do I need to test isolates with different resistance mechanisms? A: Using isolates with different resistance mechanisms allows for a more robust challenge of your AST method. 43 Qs & As Q: Why is it important to implement the CLSI revised carbapenem breakpoints? A: The carbapenem breakpoints are: Based upon new PK/PD data Can be used to guide treatment regardless of underlying resistance mechanism(s) More likely to identify carbapenemaseproducing isolates as nonsusceptible (treatment & infection control implications) Avoids using a subjective and sometimes inaccurate phenotypic test to guide treatment decisions 44 Qs & As Q: Why is it important to implement the CLSI revised cephalosporin breakpoints? A: The cephalosporin breakpoints are: Based upon new PK/PD data Can be used to guide treatment regardless of underlying resistance mechanism(s) Avoids using a limited phenotypic test to guide treatment decisions False-positives associated with multiple cephalosporinases Does not detect all cephalosporinases 45
16 Sources for Isolates CDC is sending isolates to: College of American Pathologists ATCC Isolates that you may have on hand Clinical isolates ATCC QC isolates Isolates from previous proficiency testing challenges 46 What are your plans? Our lab plans to implement the CLSI revised cephalosporin breakpoints this year Yes No Our lab plans to implement the CLSI revised carbapenem breakpoints this year Yes No 47 Acknowledgements Janet Hindler, Jim Jorgensen, Barb Zimmer Kamile Rasheed, David Lonsway, Brandi Limbago IDSA Antimicrobial Resistance Working Group CLSI The Joint Commission CAP FDA 48
17 Thank You
A Verification Study for Implementing the Revised CLSI Breakpoints. Summary. Breakpoint Differences Cephalosporin Breakpoints for Enterobacteriaceae
A Verification Study for Implementing the Revised CLSI Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance National Center for Emerging and Zoonotic Infectious Disease
More informationANTIMICROBIAL SUSCEPTIBILITY TESTING: ADVANCED
ANTIMICROBIAL SUSCEPTIBILITY TESTING: ADVANCED Romney Humphries, Ph.D., DABMM Section Chief, Clinical Microbiology University of California Los Angeles Lost Angeles, CA Susan E. Sharp, Ph.D., DABMM, FAAM
More informationNational Center for Emerging and Zoonotic Infectious Diseases The Role of Breakpoint Committees for New Drugs Perspectives from the United States
National Center for Emerging and Zoonotic Infectious Diseases The Role of Breakpoint Committees for New Drugs Perspectives from the United States Jean B. Patel, PhD, D(ABMM) Science Lead, Antibiotic Resistance
More informationVerification of Disk Diffusion Tests
Verification of Disk Diffusion Tests Objectives 1. Describe disk diffusion tests 2. Describe process of FDA clearance of susceptibility tests 3. Discuss CLIA requirements for laboratory verification of
More informationVerification of Gradient Diffusion Strips
Verification of Gradient Diffusion Strips Objectives 1. Describe gradient diffusion tests 2. Describe process of FDA clearance of susceptibility tests 3. Discuss CLIA requirements for laboratory verification
More informationCRE Laboratory Testing and CRE Lab Testing Recommendations in-depth recommendations on CRE laboratory detection
December 2014 Dear Laboratory Director, The Illinois Department of Public Health (IDPH) amended the Control of Communicable Diseases Code (77 Ill. Adm. Code 690) to require reporting of Carbapenem-Resistant
More informationESBLs and KPCs: Impact of Revised CLSI Breakpoints on testing and Reporting Algorithms
ESBLs and KPCs: Impact of Revised CLSI Breakpoints on testing and Reporting Algorithms Stephen G. Jenkins, Ph.D. Director, Clinical Microbiology Laboratories New York/Presbyterian Hospital Weill Cornell
More informationAntibiotic Susceptibility Testing (ABST/AST)
Antibiotic Susceptibility Testing (ABST/AST) Goal Offer guidance to physicians in selecting effective antibacterial therapy for a pathogen in a specific body site. Performed on bacteria isolated from clinical
More informationPERANAN MIKROBIOLOGI DALAM DIAGNOSIS PENYAKIT INFEKSI. dr. Agus Eka Darwinata, Ph.D.
PERANAN MIKROBIOLOGI DALAM DIAGNOSIS PENYAKIT INFEKSI dr. Agus Eka Darwinata, Ph.D. CLINICAL MICROBIOLOGY Clinical microbiology is the discipline of detection, characterization, and quantification of
More informationAbstract. Mary Jane Ferraro, PhD, MPH Jana M. Swenson, MMSc
January 2009 Vol. 29 No. 2 Replaces M07-A7 Vol. 26 No. 2 Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard Eighth Edition This document addresses
More informationSAMPLE. Performance Standards for Antimicrobial Susceptibility Testing
28th Edition M100 Performance Standards for Antimicrobial Susceptibility Testing This document includes updated tables for the Clinical and Laboratory Standards Institute antimicrobial susceptibility testing
More informationIMPLEMENTATION OF EUCAST BREAKPOINTS
IMPLEMENTATION OF EUCAST BREAKPOINTS BELGIAN /GDL COUNTDOWN UNTIL 1ST JANUARY 2010 : 64 DAYS Pierrette Melin, CHU of Liege Coordinator of the SBIMC-BVIKM/EUCAST microbiology working party 1 Introduction
More informationAntimicrobial Susceptibility Testing
AST Antimicrobial Susceptibility Testing Marc V. Assous, MD, PhD Shaare Zedek Med. Ctr. Universite Paris Descartes The purpose To present the methods used for AST A - Micro-dilution (ISO 20776-2006) B
More informationRapid Diagnostic Tests for Antimicrobial Resistance: Comparability of Results and Interpretation of Data
Rapid Diagnostic Tests for Antimicrobial Resistance: Comparability of Results and Interpretation of Data Christopher Teale, Animal and Plant Health Agency, UK. 12 th OIE One-Day Seminar, in association
More informationQUALITY CONTROL FOR AST: IQCP? Romney Humphries UCLA
QUALITY CONTROL FOR AST: IQCP? Romney Humphries UCLA WHAT IS QUALITY CONTROL? Procedures used to detect errors that occur due to: test system failure adverse environmental conditions variance in operator
More informationValidation of 2 nd line drug susceptibility testing. Ed Desmond California Dept. of Public Health
Validation of 2 nd line drug susceptibility testing Ed Desmond California Dept. of Public Health XDRTB!!! KwaZulu-Natal outbreak, 2006 53 HIV-infected patients, 52 deaths Average survival from specimen
More informationThe ARLN: CRE and CRPA Testing & Troubleshooting Lab Results 5/3/2017
The ARLN: CRE and CRPA Testing & Troubleshooting Lab Results 5/3/2017 After the program, send questions to ARLN@cdc.gov. Speakers Maria Karlsson, PhD, Clinical and Environmental Microbiology Branch, Division
More informationComparison of BD Phoenix to Vitek 2, MicroScan MICroSTREP, and Etest for Antimicrobial Susceptibility Testing of Streptococcus pneumoniae
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2009, p. 3557 3561 Vol. 47, No. 11 0095-1137/09/$12.00 doi:10.1128/jcm.01137-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Comparison
More informationQuality Control and Quality Assurance for Antibiotic Testing
Quality assurance Quality Control and Quality Assurance for Antibiotic Testing 26 Sep 2013 Microbiology Technical Workshop Lily Ng Siew Yong practice of assessing performance in all steps of the process
More informationNew Efforts in Combating Antibiotic Resistance The Antibiotic Resistance Laboratory Network
New Efforts in Combating Antibiotic Resistance The Antibiotic Resistance Laboratory Network Paula Snippes Vagnone MT(ASCP) July 11, 2017 MN Laboratory System Webinar Series Objectives Describe the ARLN,
More informationCarbapenem Resistance in Klebsiella pneumoniae Not Detected by Automated Susceptibility Testing
Carbapenem Resistance in Klebsiella pneumoniae Not Detected by Automated Susceptibility Testing Fred C. Tenover,* Rajinder K. Kalsi, Portia P. Williams, Roberta B. Carey,* Sheila Stocker,* David Lonsway,*
More informationM. Ben-David 1, O. Hammer 1, A.Shinderman 1, Y. Gluckman- Yavo 1, M. Fridman 1, D. Gohman 1, G. Ingber 1 and E. Zahavy 2
437 Fast Antibiotic Susceptibility Testing Utilizing a Unique Spectral Intensity Ratio Analysis via Single Fluorescence Membrane Dye Staining and Flow Cytometry M. Ben-David 1, O. Hammer 1, A.Shinderman
More informationIQCP for Disk Diffusion Antimicrobial Susceptibility Testing (AST)
IQCP for Disk Diffusion Antimicrobial Susceptibility Testing (AST) Test System: Disk Diffusion Antimicrobial Susceptibility Testing (Kirby Bauer) / Twelve Disk Diffusion Test using BBL Disks Facility:
More informationInvestigational New Drug - Groundwork for in vitro antimicrobial susceptibility testing
Investigational New Drug - Groundwork for in vitro antimicrobial susceptibility testing Erika Matuschek, Ph D Lead Scientist/Operational Manager EUCAST Development Laboratory (EDL) Växjö, Sweden ASM/ESCMID
More informationComparison of the BD Phoenix with the Vitek 2, MicroScan MICroSTREP, and Etest for Antimicrobial Susceptibility Testing of Streptococcus pneumoniae
JCM Accepts, published online ahead of print on 9 September 2009 J. Clin. Microbiol. doi:10.1128/jcm.01137-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationComparison of the BD Phoenix with the Vitek 2, MicroScan MICroSTREP, and Etest for Antimicrobial Susceptibility Testing of Streptococcus pneumoniae
JCM Accepts, published online ahead of print on 9 September 2009 J. Clin. Microbiol. doi:10.1128/jcm.01137-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All
More information9/2/15 (replaces 5/31/15 version) Page 1
Please note that some references to protocol, publications, performance data etc. are fictitious in this EXAMPLE. Please use your own DATA for your IQCP. The following represents one example of how you
More informationUse of Molecular Assays for Resistance Detection
Use of Molecular Assays for Resistance Detection Antimicrobial resistance and susceptibility are complex, and current in vitro methods have been developed to predict a microorganism s response to antibacterial
More informationon January 30, 2019 by guest
JCM Accepted Manuscript Posted Online 5 January 2018 J. Clin. Microbiol. doi:10.1128/jcm.01678-17 Copyright 2018 American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10 11 12 13 14
More informationAntibiotic Susceptibility Testing and Data Interpretation
Antibiotic Susceptibility Testing and Data Interpretation Dr Shabbir Simjee Microbiologist Co-Chair CLSI VAST Basingstoke England Bangkok, 7-8 October 2014 For clarity, these are solely my personal views/opinions
More informationAntimicrobial Susceptibility Testing Disk Diffusion
Antimicrobial Susceptibility Testing Disk Diffusion Babak Valizadeh,DCLS Babak_Valizadeh@hotmail.com 1390 / 09 / 10 2011.12.01 1 2 3 CLSI - M02-A10 / 2009 4 CLSI M100-S21 / 2011 Antimicrobial Susceptibility
More informationSAMPLE. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically
11th Edition M07 Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically This standard covers reference methods for determining minimal inhibitory concentrations of aerobic
More informationValidation of the Automated Reading and Incubation System with Sensititre Plates for Antimicrobial Susceptibility Testing
JOURNAL OF CLINICAL MICROBIOLOGY, May 2003, p. 1951 1956 Vol. 41, No. 5 0095-1137/03/$08.00 0 DOI: 10.1128/JCM.41.5.1951 1956.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationMinireview: CLSI Methods Development and Standardization Working Group Best Practices for
JCM Accepted Manuscript Posted Online 24 January 2018 J. Clin. Microbiol. doi:10.1128/jcm.01934-17 Copyright 2018 American Society for Microbiology. All Rights Reserved. 1 2 Minireview: CLSI Methods Development
More informationDr. Rukumani Devi Velayuthan Mycology Unit Co-ordinator PPUM
Antifungal sensitivity testing using VITEK 2 Dr. Rukumani Devi Velayuthan Mycology Unit Co-ordinator PPUM VITEK 2 Systems The VITEK 2 System is intended for the automated identification and susceptibility
More informationOutline. Introduction. Broth and Agar testing methods Automated susceptibility testing. Aims of antimicrobial susceptibility testing:
Outline Microbiology Technical Workshop Broth and Agar testing methods Automated susceptibility testing Dr Tan Yen Ee Registrar Singapore General Hospital 25th Sept 2013 Introduction Broth testing methods
More informationby author How to effectively report laboratory findings to clinicians (Breakpoints and Interpretation)
How to effectively report laboratory findings to clinicians (Breakpoints and Interpretation) A Vatopoulos National School of Public Health & Central Public Health Laboratory KEELPNO Antibiotic Activity
More informationIQCP for Commercial Antimicrobial Susceptibility Testing (AST) System XYZ
Please note that some references to protocol, publications, performance data etc. are fictitious in this EXAMPLE. Please use your own DATA for your IQCP. The following represents one example of how you
More informationDifficult or Tricky Antibiotic Resistance Phenotypes to Recognize. Tan Thean Yen
Difficult or Tricky Antibiotic Resistance Phenotypes to Recognize Tan Thean Yen Contents Gram-positive Staphylococcus aureus with penicillinase production Vancomycin resistant Enterococci (VRE) Staphylococcus
More informationSupplementary Information for
Supplementary Information for Direct, rapid antimicrobial susceptibility test from positive blood cultures based on microscopic imaging analysis J. Choi 1, H. Y. Jeong 2,3, G. Y. Lee 2,4, S. Han 1, S.
More informationExample # 2. IQCP for Antimicrobial Susceptibility Testing (AST) Test System: Beckman Coulter Microscan Walkaway 96. Facility: Written by: Date:
IQCP for Antimicrobial Susceptibility Testing (AST) Test System: Beckman Coulter Microscan Walkaway 96 Facility: Written by: Date: Implementation Date: This risk assessment and IQCP plan has been approved
More informationNDA Requirements: Surveillance, Clinical Trial Data, Breakpoints
NDA Requirements: Surveillance, Clinical Trial Data, Breakpoints Kevin M. Krause Director Microbiology Achaogen, Inc. Presented at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of
More informationScreening for Resistant Organisms and Infection Control
Screening for Resistant Organisms and Infection Control Dr Sonal Saxena Professor Department of Microbiology Lady Hardinge Medical College New Delhi 1 MDRO The proportion of K. pneumoniae and E. coli with
More informationApproximately 20% of the responding CLSI membership whose hospitals had greater than 200 beds was performing antifungal testing.
Vol. 28 No. 14 Replaces M27-A2 Vol. 22 No. 15 Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard Third Edition This document addresses the selection and
More informationIQCP for Streamlined ID QC of Vitek 2
IQCP for Streamlined ID QC of Vitek 2 Facility: EXAMPLE Test System: Vitek 2 Commercial Identification System Test System Primary SOPs include: GENERAL PROCEDURES: Quality Control for AST Cards and Identification
More informationComparison of different methods of determining b-lactam susceptibility in clinical strains of Pseudomonas aeruginosa
Journal of Medical Microbiology (2009), 58, 625 629 DOI 10.1099/jmm.0.005587-0 Comparison of different methods of determining b-lactam susceptibility in clinical strains of Pseudomonas aeruginosa Eva Torres,
More informationBSAC Susceptibility Testing Residential Workshop
BSAC Susceptibility Testing Residential Workshop Susceptibility Testing Methodology Insert name of presentation on Master Slide Mandy Wootton How to determine susceptibility/resistance Minimum Inhibitory
More informationGame plan. Lecture. Lab. Antibiotics Antibiotic resistance Gene transfer Transformation Transduction Conjugation
Game plan Lecture Antibiotics Antibiotic resistance Gene transfer Transformation Transduction Conjugation Lab Review temp and UV labs Growth control: alcohol, antiseptics and antibiotics Pre-lab Transformation
More informationEducational Workshops 2016
Educational Workshops 2016 Case One: Outbreak of CPE We are grateful to Suzy Fitzgerald, Consultant Microbiologist, St Vincent s University Hospital, Dublin for composing this case. 2011 Spring 2011 Sporadic
More informationCut-off Values and Species-Specific Breakpoints 12/19/2016
Welcome to Mayo Medical Laboratories Hot Topics. These presentations provide short discussion of current topics and may be helpful to you in your practice. 1 Laboratories and Professor of Laboratory Medicine
More informationEmerging Resistance in Gram- Negative Bacteria CLSI Recommendations. James H. Jorgensen, PhD
Emerging Resistance in Gram- Negative Bacteria CLSI Recommendations James H. Jorgensen, PhD Most Important Emerging or Evolving Resistance in GNs Newer ESBLs Plasmid-mediated mediated AmpCs KPCs, VIM,
More informationMIC & Etest. Dr. M. Talebi Ph.D of Bacteriology Tehran University of Medical Sciences
MIC & Etest Dr. M. Talebi Ph.D of Bacteriology Tehran University of Medical Sciences MIC The minimum inhibitory concentration (MIC) is defined as the lowest concentration of the antimicrobial agent required
More informationCARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) LABORATORY CAPACITY SURVEY. Summary Data Report
CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) LABORATORY CAPACITY SURVEY June 2015 Introduction The rise of antimicrobial-resistant organisms represents a serious threat to public health. In 2013, CDC
More informationLauren A. Darling1#, Ann M. Evans1, Kathleen A. Stellrecht1,2, Seela M. Nattanmai1,
JCM Accepted Manuscript Posted Online 20 September 2017 J. Clin. Microbiol. doi:10.1128/jcm.01185-17 Copyright 2017 American Society for Microbiology. All Rights Reserved. 1 JCM Letter to the Editor Submission
More informationMICs in TB Susceptibility Testing: Challenges and Solutions for Implementation
MICs in TB Susceptibility Testing: Challenges and Solutions for Implementation Marie-Claire Rowlinson, PhD D(ABMM) Florida Bureau of Public Health Laboratories 8 th National Conference on Laboratory Aspects
More informationCRE is not the first organism we ve had that has become resistant to antibiotics, so why is it so important? CRE resistance is complex because it can
1 Enterobacteriaceae are a large family of bacteria that are a normal part of a person's digestive system (2). Examples include Escherichia coli and species of the genera Klebsiella, Enterobacter, Serratia,
More informationUpdating Antimicrobial Susceptibility Testing Methods
Updating Antimicrobial Susceptibility Testing Methods CYNTHIA B. SCHOFIELD LEARNING OBJECTIVES: 1. Explain the physician s choice of antibiotic agents according to CLSI guidelines. 2. Define and discuss
More informationUpdating Antimicrobial Susceptibility Testing Methods
Updating Antimicrobial Susceptibility Testing Methods CYNTHIA B. SCHOFIELD LEARNING OBJECTIVES: 1. Explain the physician s choice of antibiotic agents according to CLSI guidelines. 2. Define and discuss
More informationEducational Workshop. EW08: Antimicrobial susceptibility testing practical implementation of the EUCAST breakpoints and methods
Educational Workshop EW08: Antimicrobial susceptibility testing practical implementation of the EUCAST breakpoints and methods arranged with the European Committee on Antimicrobial Susceptibility Testing
More informationStandard Operating Procedure
Subject Vitek 2 Compact Identification and Susceptibility Testing Index Number Lab-1512 Section Laboratory Subsection Regional Clinic / Affiliate Hospital Laboratories Category Departmental Contact Sanders,
More informationExtended-spectrum b-lactamases of Escherichia coli and Klebsiella pneumoniae screened by the VITEK 2 system
Journal of Medical Microbiology (2011), 60, 756 760 DOI 10.1099/jmm.0.024075-0 Extended-spectrum b-lactamases of Escherichia coli and Klebsiella pneumoniae screened by the VITEK 2 system Maria José Espinar,
More informationUrinalysis and Body Fluids CRg. Laboratory Regulation. Laboratory Regulation for Quality Assessment. Unit 1 B. Quality Assessment
Urinalysis and Body Fluids CRg Unit 1 B Laboratory Regulation Federal Regulations / Regulatory Organizations Laboratory structure / operation Quality test performed by qualified personnel to obtain quality
More informationCarbapenem-resistant Enterobacteriaceae (CRE): Surveillance and Response. David Selvage, MHS, PA-C New Mexico Department of Health March 15, 2016
Carbapenem-resistant Enterobacteriaceae (CRE): Surveillance and Response David Selvage, MHS, PA-C New Mexico Department of Health March 15, 2016 What are Carbapenem-resistant Enterobacteriaceae (CRE)?
More informationCombatting AMR: diagnostics
Combatting AMR: diagnostics Professor Neil Woodford Antimicrobial Resistance & Healthcare Associated Infections (AMRHAI) Reference Unit Crown copyright Gonorrhoea: a paradigm for better diagnostics International
More informationLABORATORY PROTOCOL. Isolation of ESBL-, AmpC- and carbapenemase-producing E. coli from caecal samples
LABORATORY PROTOCOL Isolation of ESBL-, AmpC- and carbapenemase-producing E. coli from caecal samples November 2017 Version 5 Henrik Hasman, Yvonne Agersø, Rene Hendriksen, Lina M. Cavaco (DTU Food) and
More informationINTRODUCTION METHODS Printed in Great Britain. Correspondence Mark A. Fisher
Journal of Medical Microbiology (2009), 58, 774 778 DOI 10.1099/jmm.0.006171-0 Performance of the Phoenix bacterial identification system compared with disc diffusion methods for identifying extended-spectrum
More informationAdvances in Medical Microbiology - Are the Patients Better Off?
Advances in Medical Microbiology - Are the Patients Better Off? R.P. Rennie Professor Emeritus. Laboratory Medicine and Pathology University of Alberta. Clinical Microbiology Consultant Alberta Health
More informationGuidelines for Laboratory Verification of Performance of the FilmArray Blood Culture Identification (BCID) Panel
Guidelines for Laboratory Verification of Performance of the FilmArray Blood Culture Identification (BCID) Panel Purpose The Clinical Laboratory Improvement Amendments (CLIA), passed in 1988, establishes
More informationProtocols for Laboratory Verification of Performance of the FilmArray Blood Culture Identification (BCID) Panel
Protocols for Laboratory Verification of Performance of the FilmArray Blood Culture Identification (BCID) Panel Purpose The Clinical Laboratory Improvement Amendments (CLIA), passed in 1988, establishes
More informationComparison of MicroScan WalkAway and VITEK Legacy Systems for a High-Volume Reference Laboratory
Comparison of MicroScan WalkAway and VITEK Legacy Systems for a High-Volume Reference Laboratory Merry Mariano Memphis Pathology Laboratory 5846 Distribution Drive Memphis, TN 38141 Answers for life. Introduction
More informationMedical Electronic Systems QwikCheck Beads Validation and Training Kit
Medical Electronic Systems www.mes-global.com Medical Electronic Systems QwikCheck Beads Validation and Training Kit OVERVIEW The QwikCheck Beads Validation and Training Kit is designed as a proficiency,
More informationtesting for the daily routine?
What is the role of in vitro antifungal susceptibility testing for the daily routine? ESCMID, Rome 2010 Cornelia Lass-Flörl Medical University Innsbruck Faculty disclosure Invited speaker: Pfizer, Gilead,
More informationCompetency Assessment
Competency Assessment Is Your Lab s Competency Assessment a Competent Assessment? Presented by: Jean Ball MBA, MT(HHS), MLT(ASCP) December 9, 2014 cap.org v. # Oh the places we ve been 2014 College of
More informationProtocols for Laboratory Verification of Performance of the BioFire FilmArray Blood Culture Identification (BCID) Panel
Protocols for Laboratory Verification of Performance of the BioFire FilmArray Blood Culture Identification (BCID) Panel A Laboratory Protocol for Use with Live s Purpose The Clinical Laboratory Improvement
More information2015 Focus on Compliance What You Really Need to Know About the Individualized Quality Control Plan (IQCP) and Ensuring Your Laboratory s Compliance
The Individualized Quality Control Plan (IQCP): what you need to know to ensure compliance Deborah Perry, M.D. Objectives Describe changes to the quality control regulations Explain how the CAP has implemented
More informationAntimicrobial Susceptibility Testing Paradigms: Current Status and Future Directions
Antimicrobial Susceptibility Testing Paradigms: Current Status and Future Directions Robert J. Tibbetts Department of Pathology, Henry Ford Health System, Detroit, MI 48202. Corresponding Author Robert
More informationEzy MIC Strip FEATURES AND ADVANTAGES
Imipenem with & without EDTA Ezy MIC Strips (IPM+EDTA/IPM) (Imipenem + EDTA: 1-64 mcg/ml) (Imipenem : 4-256 mcg/ml) Antimicrobial Susceptibility Testing For In Vitro Diagnostic use EM078 Not for Medicinal
More informationLABORATORY PROTOCOL. Isolation of ESBL-, AmpC- and carbapenemase-producing E. coli from fresh meat
LABORATORY PROTOCOL Isolation of ESBL-, AmpC- and carbapenemase-producing E. coli from fresh meat February 2018 Version 6 Version 6 reviewed and updated by: Rene S. Hendriksen and Valeria Bortolaia Authors
More informationAbstract. Introduction
ORIGINAL ARTICLE BACTERIOLOGY A sensitive and specific phenotypic assay for detection of metallo-blactamases and KPC in Klebsiella pneumoniae with the use of meropenem disks supplemented with aminophenylboronic
More informationThe Laboratory Diagnosis of Enterobacteriaceae that produce Carbapenemases. and Johann DD Pitout 1-3
JCM Accepts, published online ahead of print on 19 September 2012 J. Clin. Microbiol. doi:10.1128/jcm.02117-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 The Laboratory Diagnosis
More informationAre There Non-Carbapenem β-lactam Options for Treating ESBL Infections?
CIDEIM Are There Non-Carbapenem β-lactam Options for Treating ESBL Infections? Pranita D. Tamma, M.D., M.H.S. Assistant Professor, Pediatrics Director, Pediatric Antimicrobial Stewardship Program CIDEIM
More informationIMP-Producing Carbapenem-Resistant Klebsiella pneumoniae in the United States
JOURNAL OF CLINICAL ROBIOLOGY, Dec. 2011, p. 4239 4245 Vol. 49, No. 12 0095-1137/11/$12.00 doi:10.1128/jcm.05297-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. IMP-Producing
More informationNational Pilot Study of Carbapenemase-producing Carbapenem Resistant Enterobacteriaceae (CRE) in Critical Care Units in the Republic of Ireland
National Pilot Study of Carbapenemase-producing Carbapenem Resistant Enterobacteriaceae (CRE) in Critical Care Units in the Republic of Ireland Study Protocol Version 1.4 June 2011 Table of Contents Table
More informationCAP Regulatory Potpourri for Microbiologists. Christi Wojewoda, MD Director of Clinical Microbiology 2/2/19
CAP Regulatory Potpourri for Microbiologists Christi Wojewoda, MD Director of Clinical Microbiology 2/2/19 Disclosures Vice Chair of the CAP Microbiology Committee Immediate Past Vice Chair of the CAP
More informationMeasurement Uncertainty Guide. ISO Accreditation Program
Measurement Uncertainty Guide ISO 15189 Accreditation Program Background Why This is Necessary The ISO 15189:2012 standard contains enhanced expectations regarding measurement uncertainty (MU) in clause
More informationM. Ben-David 1, O. Hammer 1, A.Scinderman 1, Y. Gluckman-Yavo 1, M. Fridman 1, D. Gohman 1, G. Ingber 1 and E. Zahavy 2
441 Rapid Gram Negative Antimicrobial Susceptibility Testing Directly from Positive Blood Culture based on a Unique Spectral Intensity Ratio Analysis via Single Fluorescence Membrane Dye Staining and Flow
More informationby author ESCMID Online Lecture Library Implementation of EUCAST antimicrobial susceptibility testing methods Gunnar Kahlmeter, Derek Brown
Implementation of EUCAST antimicrobial susceptibility testing methods Gunnar Kahlmeter, Derek Brown Izmir, February 2011 Implementation of EUCAST antimicrobial susceptibility testing methods EUCAST National
More informationCDC Antibiotic Resistance Laboratory Network- Southeast Region. Nailah Smith, DVM, MPH, Epidemiologist
CDC Antibiotic Resistance Laboratory Network- Southeast Region Nailah Smith, DVM, MPH, Epidemiologist Overview ARLN Introduction Southeast Regional Laboratory Overview ARLN Alert Values Isolate flow CRE
More informationIntroduction to Software for Analysis of Susceptibility Experiments
1 / 31 Introduction to Software for Analysis of Susceptibility Experiments With Open Questions and Discussion Glen DePalma gdepalma@purdue.edu Bruce A. Craig bacraig@purdue.edu Clinical and Laboratory
More informationCLIA Corner. In This Issue... Common Deficiencies. Proficiency Testing Personnel Micro Quality Control
CLIA Corner The University of Iowa Hygienic Laboratory First Quarter 2006 Iowa CLIA Surveyors: Nancy Grove, BS, MT(ASCP) & Kristine Rotzoll, BS, MT(ASCP) In This Issue... Common Deficiencies Proficiency
More informationNCCLS Standards for Antimicrobial Susceptibility Tests
CE Update Microbiology III NCCLS Standards for Antimicrobial Susceptibility Tests Clyde Thornsberry, PhD T he most requested test of the clinical microbiology laboratory today is probably t h e antimicrobial
More informationCharacterization of the modified Hodge testpositive isolates of Enterobacteriaceae in Taiwan
Journal of Microbiology, Immunology and Infection (2013) 46, 35e40 Available online at www.sciencedirect.com journal homepage: www.e-jmii.com ORIGINAL ARTICLE Characterization of the modified Hodge testpositive
More informationEmpfindlichkeitstestung bei Pilzen Neuigkeiten? Bericht aus einem EUCAST AFST (yeasts and moulds) Netzwerk-Laboratorium
Empfindlichkeitstestung bei Pilzen Neuigkeiten? Bericht aus einem EUCAST AFST (yeasts and moulds) Netzwerk-Laboratorium EUCAST reloaded 6.0 Follow-up Workshop 23.03.2017 Cornelia Lass-Flörl Division of
More informationINNOVATIVE SCIENCE DRIVES ANTIBIOTIC LEADERSHIP. Corporate Presentation October 2018 Nasdaq: AKAO
INNOVATIVE SCIENCE DRIVES ANTIBIOTIC LEADERSHIP Corporate Presentation October 2018 Nasdaq: AKAO Forward Looking Statements This presentation contains forward-looking statements. All statements other than
More informationcustomized solutions
Microbiology System customized solutions Maximizing performance through accurate, true MIC results and customizable test options TREK Diagnostic Systems Susceptibility and Identification Testing System
More informationbiomérieux, Inc. acquires Bacterial Barcodes, Inc.
October 2006 Vol. 3 No. 4 In this issue: NucliSENS...2 VITEK 2...4 Tradeshow News...7 For more information about DiversiLab, go to www.biomerieux-usa.com/barcodes/ biomérieux, Inc. acquires Bacterial Barcodes,
More informationNordicAST Bacteroides AST Study 2018
NordicAST Bacteroides AST Study 2018 Background Bacteroides fragilis is the most common anaerobic species causing invasive infections (1). In addition to possessing intrinsic resistance mechanisms against
More information6/21/2012 Speaker Hannah Wexler, PhD, Objectives Continuing Education Credit program and evaluation by 07/21/ an Archived Program 612an
Anaerobic Bacteria Susceptibility Testing 6/21/2012 Speaker Hannah Wexler, PhD, Adjunct Professor, Department of Medicine UCLA School of Medicine, Los Angeles, CA Dr. Hannah Wexler is an Adjunct Professor
More informationKey words: ESBLs; Ceftriaxone; Escherichia coli; MICs; Bacteremia
JCM Accepts, published online ahead of print on 16 April 2014 J. Clin. Microbiol. doi:10.1128/jcm.00716-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 1 2 Title: Determining
More information